[PDF] Top 20 Mutational analysis of KRAS and NRAS in metastatic colorectal cancer
Has 10000 "Mutational analysis of KRAS and NRAS in metastatic colorectal cancer" found on our website. Below are the top 20 most common "Mutational analysis of KRAS and NRAS in metastatic colorectal cancer".
Mutational analysis of KRAS and NRAS in metastatic colorectal cancer
... analyzed in both KRAS and NRAS genes and nine mutations were found in KRAS and eight in NRAS, representing four different amino acid substitutions: ... See full document
88
Mutation detection in tumor-derived cell free DNA anticipates progression in a patient with metastatic colorectal cancer
... presentation: In an exploratory case of a 57-year-old man diagnosed with metastatic sigmoid adenocarcinoma, we used a hotspot panel of cancer-associated gene mutations to identify ... See full document
6
KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.
... to KRAS gene, BRAF also encodes proteins that act in the RAS-RAF-MAPK signaling ...Western and Chinese, reported that BRAF mutations were detected in ...5.0%–10.0% of CRC ...studies ... See full document
7
Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer.
... before and after treatment. Correlation between the changes of size, HU, and mSUV was assessed with Pearson’s correlation ...point of HU change predicting any decrease in mSUV ... See full document
13
Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis.
... NPM1 and PDGFRA when the least stringent QBVD threshold was applied (QBVDi = ...100% of samples had mutations in PDGFRA and APC, while 37.5% and 75% of patient samples had FGFR3 ... See full document
10
Mutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue.
... source of tumor material from patients with ...is of great clini- cal importance regarding the increasing number of adjuvant treatment options for patients with metastatic carcinomas, ... See full document
12
Personalizing medicine for metastatic colorectal cancer: Current developments
... for KRAS wild-type (WT) gene ...option in combination with some of the regi- mens ...order in which these drugs were received. After the first progression of the disease, the ... See full document
8
Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
... presence of lymph node metastases and pMMR tumors stratified by KRAS mutation ...with KRAS mutation demonstrated more positive lymph nodes and pTNM III-IV stage of dis- ease than ... See full document
12
EMAST is associated with a poor prognosis in microsatellite instable metastatic colorectal cancer.
... EMAST and MSI is not widely accepted. We found a high frequency of EMAST in MSI tumors, which was confirmed in a analysis of the existing literature in stage I-IV CRC (Fig ... See full document
13
The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.
... cases) and wild-type BRAF/NRAS group (80 ...effect of BRAF mutation alone on patient survival in this report. In a very similar study, Houben et al [51] evaluated the effect of ... See full document
10
Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status
... of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung ... See full document
13
PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis.
... sensitivity and specificity enable effective exclusion of patients with mutant KRAS, as well as reduce drug side effects and increase PFS and mOS in the wild-type KRAS ... See full document
7
Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges
... unresectable metastatic colorectal cancer live for a median of three years when treated with standard ...guiding cancer-directed treatment of this disease comes from phase III ... See full document
7
Role of PLCy1 in the resistance mechanism to Anti-EGFR therapy in metastatic colorectal cancer
... efficacy of conventional chemotherapy in metastatic CRC over the last decade, a large number of patients still do not benefit from these ...treatments. KRAS mutations are recognized as ... See full document
61
Targeting metastatic colorectal cancer with PLGA nanoparticles carrying MACC1 siRNA
... than in the membrane. Looking again to Figure 17B, there is exposed a graph of the Normalized Frequency (Normalized number of cells) VS Internalization Score for each sample, where it is possible to ... See full document
126
Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
... error in reference ...study of panitumumab with fluorouracil, leucovorin, and irinotecan(FOLFIRI) compared with FOLFIRI alone as second- line treatment in patients with metastaticcolorectal ... See full document
2
"Comparison of Methodologies for Kras Mutation Detection in Metastatic Colorectal Cancer".
... synthesized in the late 1950s and was for a long time the only available drug to treat ...inactive in its patent form and converted within the cell to the cytotoxic metabolite ... See full document
58
PHARMACOECONOMICS ANALYSIS of TREATMENT of METASTATIC COLORECTAL CANCER WITH BEVACIZUMAB in BRAZIL
... costs and outcomes of lapatinib associated to capecitabine (LAP/CAP) versus capecitabine alone (CAP) or trastuzumab associated to capecitabine (TRAST/CAP) versus capecitabine alone in the treatment ... See full document
1
SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.
... risk of treatment failure in a case-control study[26]; therefore, we accounted for smoking status in the multivariate ...(OR) and their 95% confidence interval (CI) were calculated as ... See full document
10
The role of KRAS mutations signalling in autophagy control in Colorectal Carcinomas
... subfamily of MAPK signalling pathway have a large involvement in the pathogenesis, progression and oncogenic behaviour of CRC ...subfamily of MAPK signalling pathway, when activated, ... See full document
96
temas relacionados